Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer

Table 1

Patient characteristics (35 patients).

Variables	<40 Gy (n = 14)	≥40 Gy (n = 21)	Total (n = 35)	P value*
Age	72 (66–85)	70 (55–93)	71.5 (55–93)^†	0.206
Baseline PSA (ng/mL)	72.0 (0.3–964)^†	11.0 (0.1–142)^†	34.0 (0.1–964)^†	0.047
ECOG PS
0–1	8	21	29 (82.9%)	0.002
≥2	6	0	6 (17.1%)
No. of bone metastases	3 (1–5)^†	2 (1–5)^†	2 (1–5)^†	0.218
CRPC	5 (35.7%)	2 (9.5%)	7 (20%)	0.090
Pain
Yes	9 (64.3%)	7 (33.3%)	16 (45.7%)	0.094
Spinal cord compression
Yes	2 (14.3%)	0	2 (5.7%)	0.153
Pathologic fracture
Yes	4 (28.6%)	1 (4.8%)	4 (14.3%)	0.134
Oligostatus
oligo-recurrence group	2 (14.3%)	16 (76.2%)	18 (51.4%)	0.000

Abbreviations. PSA: prostate-specific antigen; ECOG PS: Eastern Cooperative Oncology Group performance status; CRPC: castration-resistant prostate cancer.
^†Median (range).
^*Significance of difference between groups determined by chi-square test or Fisher exact test, as appropriate. P < 0.05 considered significant.